依帕司他对2型糖尿病自主神经病变患者静息心率和心率变异性的影响被引量：1

下载PDF

导出

摘要目的观察依帕司他对2型糖尿病自主神经病变(DCAN)患者静息心率(RHR)和心率变异性(HRV)的影响和安全性。方法选择符合诊断标准的DCAN患者56例,随机分为观察组和对照组,每组28例。2组均予以口服降糖药和(或)胰岛素控制血糖,观察组加用依帕司他治疗12周,观察比较2组RHR、HRV等指标的变化和不良反应发生情况。结果观察组治疗前后RHR、总体标准差(SDNN)、均值标准差(SDANN)、差值均方平方根(RMSSD)、爱丁堡指数(PNN50)比较差异有统计学意义(P<0.01);对照组治疗前后RHR、HRV各指标比较差异无统计学意义(P>0.05);2组治疗后RHR、SDANN、SDANN、RMSSD、PNN50比较差异有统计学意义(P<0.01)。观察组除1例发生腹胀外未见其他不良事件,2组治疗前后血、尿、大便常规及肝肾功能检查均无明显变化。结论依帕司他能有效改善DCAN患者自主神经病变,且临床安全性好。

作者李梅黄强

机构地区浙江省嘉善县第二人民医院浙江省嘉善县中医院

出处《临床合理用药杂志》 2018年第17期69-70,共2页 Chinese Journal of Clinical Rational Drug Use

关键词依帕司他 2型糖尿病自主神经病变静息心率心率变异性

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献2

1阎朝丽,王凤岐,谢玉环,候俊秀.颈动脉内膜一中层厚度与2型糖尿病大血管病变及危险因素的关联[J].中国糖尿病杂志,2001,9(3):185-185. 被引量：32
2李平,马建华,高佳麟,余江毅,缪珩,孙媛,李伟,梁军,王雪琴,于建成,杨涛,王坚,孙子林,吕国萍,徐宁,成兴波,朱大龙.依帕司他治疗糖尿病周围神经病变安全性和有效性的随机、对照、多中心临床研究[J].中华内分泌代谢杂志,2015,31(9):743-747. 被引量：44

二级参考文献16

1Tesfaye S, Boulton A J, Dyek PJ, et al. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments [ J ]. Diabetes Care, 2010,33 ( 10 ) :2285-2293.
2Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [ J ]. N Engl J Med, 1993,329(14) :977-986.
3Greene DA, Sima AA, Stevens MJ, et al. Complications: neuropathy, pathogenetic considerations [ J ]. Diabetes Care, 1992,15 (12) : 1902- 1925.
4Schemmela KE, Padiyarab RS, D' Souzab JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review [J]. J Diabetes Complications, 2010,24(5) :354-360.
5Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy [ J ]. Clin Neurol Neurosurg, 1992,94 ( 2 ) : 105- 111.
6Vinik AI, Mehrabyan A. Diabetic neuropathies [ J ]. Med Clin North Am, 2004,88(4) :947-999.
7Oates PJ. Polyol pathway and diabetic peripheral neuropathy [ J ]. Int Rev Neurobiol, 2002,50 ( 1 ) : 325-392.
8Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy : a 52-week multicenter placebo-controlled double-blind parallel group study [ J ]. Diabetes Care, 2001,24 (10) : 1776-1782.
9Hotta N, Sakamoto N, Shigeta Y, et al. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan : multicenter study [ J ]. J Diabetes Complications, 1996,10 ( 3 ) : 168-172.
10Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, muhicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trim [ J ]. Diabetes Care, 2006,29 (7) :1538-1544.